Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Ophthalmic Surgery
  •  Otolaryngology - Head and Neck Surgery
  •  Gastroenterological Surgery
  •  Cardiovascular Surgery
  •  Vascular Surgery
  •  Robotic Surgery
  •  Breast Surgery
  •  Oral and Maxillofacial Surgery

Abstract

Citation: Clin Surg. 2022;7(1):3596.Research Article | Open Access

Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, Lehmann J, Strassburg CP and Trebicka J

Department of Internal Medicine I, University of Bonn, Germany
Medical Department B, University Clinic Münster, Germany
European Foundation for Study of Chronic Liver Failure, Spain
#Both authors contributed equally to this work

*Correspondance to: Christian Jansen 

 PDF  Full Text DOI: 10.25107/2474-1647.3596

Abstract

Background: Ascites is the common cause of decompensation in patients with cirrhosis. It has been ascertained that 5% to 10% of patients with end stage liver disease showed in case of compensation the develop of ascites every year. The alfapump© reduces the need for large volume paracentesis and can improve life quality. The aim of our study was to assess the role of the use of Non-Selective Beta-Blocker (NSBB) characteristics and outcomes of patients with cirrhosis receiving alfapump© and to find predictors of a longer life in a palliative concept. Methods: Seventeen (13 males) patients with liver cirrhosis receiving an alfapump© were included in this case-series. Clinical parameters were assessed before the insertion of the alfapump© and during follow-up. As part of the follow-up, all patients received the standard of care as recommended by European Association for the Study of the Liver and DGVS. Results: Could generally be identified as the cause of death. If the patients were stratified according to the use of a non-selective beta-blocker, we can see that the group taking non-selective beta blocker had a longer survival. These data to verify previous finding that NSBB in this very high-risk patient may delay infections and improve outcome. Conclusion: This study suggests a protective effect of NSBB in patients after implantation of an alfapump©. Although confirmation is needed, this may help management of patients receiving the device.

Keywords

Liver; Cirrhosis; Ascites; Alfapump©; Non-selective beta blocker

Cite the article

Jansen C, Wagner RM, Praktiknjo M, Chang J, Böhling N, Kaczmarek D, et al. Non-Selective Beta Blocker Therapy Improves Survival in Patients Receiving Alfapump©. Clin Surg. 2022; 7: 3596..

Search Our Journal

Journal Indexed In

Articles in PubMed

Risk Factors for Visual Impairment in an Uninsured Population and the Impact of the Affordable Care Act
 PubMed  PMC  PDF  Full Text
Monitoring an Ongoing Enhanced Recovery after Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Protein Identification and Haplotype Description of Homozygote Mutation Causing Congenital Plasminogen Deficiency
 Abstract  PDF  Full Text
Effect of Home Blood Pressure Telemonitoring Plus Additional Support on Blood Pressure Control: A Randomized Clinical Trial
 Abstract  PDF  Full Text
View More...